Lappaol F, an anticancer agent, inhibits YAP via transcriptional and post-translational regulation

Context Lappaol F (LAF), a natural lignan from Arctium lappa Linné (Asteraceae), inhibits tumour cell growth by inducing cell cycle arrest. However, its underlying anticancer mechanism remains unclear. Objective The effects of LAF on the Hippo-Yes-associated protein (YAP) signalling pathway, which p...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiao Li (Author), Yi-Ying Lin (Author), Jia-Yi Tan (Author), Kang-Lun Liu (Author), Xiao-Ling Shen (Author), Ying-Jie Hu (Author), Rui-Yi Yang (Author)
Format: Book
Published: Taylor & Francis Group, 2021-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_dbd8a5549d6c47358d30bc0ef73e4e5b
042 |a dc 
100 1 0 |a Xiao Li  |e author 
700 1 0 |a Yi-Ying Lin  |e author 
700 1 0 |a Jia-Yi Tan  |e author 
700 1 0 |a Kang-Lun Liu  |e author 
700 1 0 |a Xiao-Ling Shen  |e author 
700 1 0 |a Ying-Jie Hu  |e author 
700 1 0 |a Rui-Yi Yang  |e author 
245 0 0 |a Lappaol F, an anticancer agent, inhibits YAP via transcriptional and post-translational regulation 
260 |b Taylor & Francis Group,   |c 2021-01-01T00:00:00Z. 
500 |a 1388-0209 
500 |a 1744-5116 
500 |a 10.1080/13880209.2021.1923759 
520 |a Context Lappaol F (LAF), a natural lignan from Arctium lappa Linné (Asteraceae), inhibits tumour cell growth by inducing cell cycle arrest. However, its underlying anticancer mechanism remains unclear. Objective The effects of LAF on the Hippo-Yes-associated protein (YAP) signalling pathway, which plays an important role in cancer progression, were explored in this study. Materials and methods Cervical (HeLa), colorectal (SW480), breast (MDA-MB-231) and prostate (PC3) cancer cell lines were treated with LAF at different concentrations and different durations. BALB/c nude mice bearing colon xenografts were intravenously injected with vehicle, LAF (10 or 20 mg/kg) or paclitaxel (10 mg/kg) for 15 days. The expression and nuclear localisation of YAP were analysed using transcriptome sequencing, quantitative PCR, western blotting and immunofluorescence. Results LAF suppressed the proliferation of HeLa, MDA-MB-231, SW480 and PC3 cells (IC50 values of 41.5, 26.0, 45.3 and 42.9 μmol/L, respectively, at 72 h), and this was accompanied by significant downregulation in the expression of YAP and its downstream target genes at both the mRNA and protein levels. The expression of 14-3-3σ, a protein that causes YAP cytoplasmic retention and degradation, was remarkably increased, resulting in a decrease in YAP nuclear localisation. Knockdown of 14-3-3σ with small interfering RNA partially blocked LAF-induced YAP inhibition and anti-proliferation effects. In colon xenografts, treatment with LAF led to reduced YAP expression, increased tumour cell apoptosis and tumour growth inhibition. Conclusion LAF was shown to be an inhibitor of YAP. It exerts anticancer activity by inhibiting YAP at the transcriptional and post-translational levels. 
546 |a EN 
690 |a yes-associated protein 
690 |a 14-3-3σ 
690 |a tumour suppression 
690 |a cell proliferation 
690 |a apoptosis 
690 |a colon xenografts 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Pharmaceutical Biology, Vol 59, Iss 1, Pp 619-628 (2021) 
787 0 |n http://dx.doi.org/10.1080/13880209.2021.1923759 
787 0 |n https://doaj.org/toc/1388-0209 
787 0 |n https://doaj.org/toc/1744-5116 
856 4 1 |u https://doaj.org/article/dbd8a5549d6c47358d30bc0ef73e4e5b  |z Connect to this object online.